GlassScriptPhysician profile
Nima Ramezan Arab
NPI 1699705772
$7,626.71
in general payments reported to CMS, 2019-2025
50 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $406 · 2021: $1,123 · 2022: $1,193 · 2023: $1,359 · 2024: $1,441 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,193 · Education: $92.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,193.01 |
| Education | $92.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,055.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,015.41 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $549.75 | 2020-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $465.75 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Alexion Pharmaceuticals, INC. | $415.52 | 2019-2025 | Ultomiris, Soliris, Koselugo |
| Ucb, INC. | $408.26 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Sk Life Science, INC. | $339.81 | 2021-2025 | |
| Pfizer INC. | $280.58 | 2023-2025 | |
| Genentech USA, INC. | $259.44 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $166.66 | 2019-2024 | Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $162.73 | 2020-2024 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $161.12 | 2021-2025 | Wainua |
| Allergan, INC. | $160.59 | 2019-2022 | |
| Lundbeck LLC | $157.85 | 2022-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $157.17 | 2021-2025 | Nuplazid |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Ramezan Arab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.